BOLDENONE UNDECYLENATE 200mg/ml

Boldenone Undecylenate 200mg/ml

Molecular Formula:

C30H44O3

Molecular Weight:

452.679 g/mol

Structure:

DESCRIPTION

Boldenone Undecylenate Injection is an injectable anabolic preparation. After injection, Boldenone Undecylenate is gradually released from the intramuscular depot and subse- quently hydrolyzed into dihydroboldenone.

INDICATIONS

As an anabolic steroid.

Certain cases of disseminated breast cancer in women. Osteoporosis due to androgen deficiency in hypogonadal males.

CONTRAINDICATIONS

Not intended for use in children.

Known or suspected prostatic carcinoma and mammary carcinoma in the male.

Not intended for use in female patients other than those with disseminated breast cancer.

Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure,hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic carcinoma.

DOSAGE AND DIRECTIONS FOR USE

Boldenone Undecylenate injection should be administered by deep intramuscular injec- tion.

Adult dose: 75 mg to 150 mg every three weeks.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:

Virilization which appears in sensitive women as hoarseness, acne, hirustism and in- creased libido; in prepubertal boys as an increased frequency of erections and phallic en- largement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometime irreversible deepening of the voice.

Other adverse reactions may include:

Oligospermia and decreased ejaculatory volume.

Suppression of ovarian activity, atrophy of the breasts and endometrial tissue Amenorrhea and inhibition of spermatogenesis

Water and salt retention Premature epiphyseal closure

If signs of virilization develop, treatment should be discontinued

Increase in nitrogen retention and skeletal weight Oedema

Increased vascularity of the skin Increased growth of the bone

Elderly males may become over stimulated

Patients with the following conditions should be monitored:

Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention

Diabetes, since anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other antidiabetic drugs

Incomplete stature growth, since anabolic steroids may induce hypercalcemia and hy- percalciuria in these patients

Liver dysfunction

DRUG INTERACTIONS

Liver enzyme-inducing agents may reduce the effects of Boldenone by enhancing its effects in the liver.

PRESENTATION

200 mg/ml, 1 ml cartridges

STORAGE

Store in a cool dry place (30 C± 2 C). Protect from light. Warming and rotating the vial between the palms of the hands will redissolve any crystals that may have formed during storage at low temperatures.